Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01588431
Title Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ahmad Wehbe
Indications

head and neck cancer

Therapies

Cetuximab + Cisplatin + Docetaxel

Bevacizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.